

EXHIBIT 2

LIBRARY OF CONGRESS

*Copyright Office
of the United States*

WASHINGTON, D.C.

THIS IS TO CERTIFY that on May 7, 2009 a claim to copyright a work identified as **ROYALTYSTAT WEBSITE ROYALTY TABLEAU** was registered under **TX 7-233-781**. This work was registered in accordance with provisions of the United States Copyright Law (Title 17 United States Code).

THIS IS TO CERTIFY FURTHER, that the attached is an additional certificate of this work.

IN WITNESS WHEREOF the seal of this Office is affixed hereto on November 20, 2015.

Maria A. Pallante
Register of Copyrights

Jarletta Walls

By: Jarletta Walls
Supervisory Copyright Specialist
Records Research and Certification Section
Office of Public Records and Repositories

Use of this material is governed by the U.S. copyright law 17 U.S.C. 101 et seq.

EXHIBIT

C

Certificate of Registration



This Certificate issued under the seal of the Copyright Office in accordance with title 17, *United States Code*, attests that registration has been made for the work identified below. The information on this certificate has been made a part of the Copyright Office records.

Maria A. Pallante

Register of Copyrights, United States of America

Registration Number
TX 7-233-781

Effective date of
registration:
May 7, 2009

Title _____

Title of Work: Royaltystat website royalty tableau

Completion/ Publication _____

Year of Completion: 2009

Date of 1st Publication: May 7, 2009

Nation of 1st Publication: United States

Author _____

Author: Royaltystat LLC

Author Created: text

Work made for hire: Yes

Citizen of: United States

Domiciled in: United States

Copyright claimant _____

Copyright Claimant: Royaltystat, LLC

5404 Blackistone Road, Bethesda, MD, 20816-1821, United States

Rights and Permissions _____

Organization Name: Royaltystat, LLC

Name: Ednaldo A. Silva

Email: esilva@royaltystat.com

Address: 5404 Blackistone Road

Bethesda, MD 20816-1821 United States

Certification _____

Name: Marcus G. Theodore, agent

Date: May 7, 2009

Correspondence: Yes

Registration #: TX0007233781

Service Request #: 1-190968612

Royaltystat, LLC
Ednaldo A. Silva
5404 Blackistone Road
Bethesda, MD 20816-1821 United States

LIBRARY OF CONGRESS
Copyright Office
of the United States
 WASHINGTON, D.C.

THIS IS TO CERTIFY that the attached color photocopies are a true representation of the work entitled **ROYALTYSTAT WEBSITE ROYALTY TABLEAU** deposited in the Copyright Office with claim of copyright registered under number **TX 7-233-781**


THIS IS TO CERTIFY FURTHER, that due to the nature of the work deposited, the attached color photocopies are the best possible electrostatic positive prints available.

IN WITNESS WHEREOF, the seal of this Office is affixed hereto on November 20, 2015.

Maria A. Pallante
 Register of Copyrights

Jarletta Walls

By: Jarletta Walls
 Supervisory Copyright Specialist
 Records Research and Certification Section
 Office of Public Records and Repositories




Use of this material is governed by the U.S. law 17 U.S.C. 101 et seq.

of all right
 ademarks
 ection with
 al expect

tangible
 to exclusi
 Pharmaci
 ind domai
 nufacture,
 iving oral

Delete f

Edit
 Library



Royalty Rates for Licensing Intangibles

[Folders](#) [Search](#) [Edit Login](#) [Logoff](#)
[Create Invoice](#) [Library](#) [Contact](#)
[Saved Searches](#)

RoyaltyStat® On-Line 2834 - Patent Archive contains 9 agreement(s).

You have 818 agreements remaining on your limit of 1000 agreement(s).

[Statistics](#) [Go](#) [New Folder](#)
[Move Docs To](#) [Copy Docs To](#) [Go To](#)

2834 - Patent (9)

[Delete From Archive](#)

Sort Archive By: RoyaltyRate


[Go](#)




Document/Agreement Details


Reference:	15516	Effective Date:	08/05/2007	Licensed Intangible
SIC Code:	2834	SEC Filing Date:	08/14/2008	Amendment to exclusive license to use "Gamma Pharmaceuticals"
SEC Filing:	Gamma Pharmaceuticals Inc	Royalty Rate:	1.50 %	trademarks and domain names to develop, manufacture, market and sell fast dissolving oral strips and oral gel.
SEC Filing:	10-Q PDF	Royalty Base:	Net Sales	
Agreement Type:	Trademark	Tiered Royalty:	Yes	
Licensor:	Jugular, Inc.			
Licensee:	Gamma Pharmaceuticals, Inc.			
Duration:	14 year(s)	Exclusive:	Exclusive	
Other Payments:				
Territory:	Worldwide			
Reference:	16627	Effective Date:	02/15/2005	Assignment of all rights, title, and interest in trademarks "Humbid,"
SIC Code:	2834	SEC Filing Date:	05/13/2005	used in connection with pharmaceutical expectorant products.
SEC Filing:	Adams Respiratory Therapeutics, Inc.	Royalty Rate:	2.00 %	
SEC Filing:	S-1/A PDF	Royalty Base:	Net Sales	
Agreement Type:	Trademark	Tiered Royalty:	Yes	
Licensor:	Cornerstone Biopharma, Inc.			
Licensee:	Adams Laboratories, Inc.			
Duration:	3 year(s)	Exclusive:	Unknown	

Other Payments:		Unknown		Exclusive license to use the "BioFIT" trademark to use, market, manufacture, sell and distribute herbal dietary supplements in tablet, 2-piece hard-shell and gelatin capsules delivery forms, including St. Johns Wort, Echinacea, Saw Palmetto, Ginseng and Ginkgo Biloba initially.	
Territory:					
Reference:	9655	Effective Date:	10/30/1998		
SIC Code:	2835	SEC Filed Date:	05/18/1999		
SEC Filing:	Paracelsian Inc /De/	Royalty Rate:	3.00 %		
SEC Filing:	10-KSB/A PDF	Royalty Base:	Net Sales		
Agreement Type:	Trademark	Tiered Royalty:	Yes		
Licensor:	Paracelsian, Inc.				
Licensee:	R.P. Scherer North America				
Duration:	1.5 Year(s)	Exclusive:	Exclusive		
Other Payments:	Milestone payments are \$50,000 for each of the 1st 5 customers to accept the initial products. Art. 6.1. New products milestone payments are \$50,000 for each new product upon acceptance by 2 customers. Art. 6.2.				
Territory:	Canada; Mexico; United States				
Reference:	255	Effective Date:	01/1993		Exclusive trademark license to promote, sell and sublicense prescription or over-the-counter pharmaceutical specialties containing Modafinil.
SIC Code:	2834	SEC Filed Date:	08/16/1999		
SEC Filing:	Cephalon Inc	Royalty Rate:	4.00 %		
SEC Filing:	10-Q PDF	Royalty Base:	Net Sales		
Agreement Type:	Trademark	Tiered Royalty:	Yes		
Licensor:	Genelco				
Licensee:	Cephalon, Inc.				
Duration:	99 year(s)	Exclusive:	Exclusive		
Other Payments:					
Territory:	Mexico; United States				
Reference:	15596	Effective Date:	07/21/1993		Amendment to exclusive trademark license.
SIC Code:	2834	SEC Filed Date:	08/16/1999		
SEC Filing:	Cephalon Inc	Royalty Rate:	4.00 %		
SEC Filing:	10-Q PDF	Royalty Base:	Net Sales		
Agreement Type:	Trademark	Tiered Royalty:	Yes		
Licensor:	Genelco SA				
Licensee:	Cephalon, Inc.				
Duration:	20 year(s)	Exclusive:	Exclusive		
Other Payments:					
Territory:	Europe				
Reference:	1949	Effective Date:	12/01/2000		Nonexclusive license to use the trademarks in connection with the
SIC Code:	2834	SEC Filed Date:	11/14/2000		

6		SEC Filing:	Carrington Laboratories Inc	Royalty Rate:	5.00 %	manufacture, marketing, advertisement, promotion and distribution of dermal management products under the trademarks Carrington, CarraGauze, CarraSorb, CarraCinamate, CarraFilm, SurgiSutures, CarraSmart, CarraDres, CarraColloid, CarraKlenz, UltraKlenz, MicroKlenz, CarraFoam, CarraWash, CarraFree, CarraScent, CarraFresh, CarraDerm, DiaB, and RadiaCare.
		Agreement Type:	10-Q PDF	Royalty Base:	Net Sales	
7		Licensors:	Carrington Laboratories, Inc.	Tiered Royalty:	Yes	Exclusive patent, technology and know-how license to use the "Donovex" trademark to import, store, distribute, use and sell products containing the pharmaceutical compound Calcipotriene, a vitamin D analogue with the formula C27H40O3 for human therapeutic use in the field of dermatology, with right to sublicense.
		Licensee:	Medline Industries, Inc.	Royalty Rate:	10.00 %	
8		Duration:	5 year(s)	Exclusive:	Non-Exclusive	Exclusive patent license to promote, distribute, market, advertise, sell or offer the extended release ciprofloxacin HCl pharmaceutical product under the "Proquin XR" trademark.
		Other Payments:	Canada; Puerto Rico; United States; Virgin Islands			
9		Territory:	4660	Effective Date:	09/01/2005	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Reference:	2834	SEC Filed Date:	01/05/2004	
10		SEC Filing:	Galen Holdings Plc	Royalty Rate:	10.00 %	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Agreement Type:	20-F/A PDF	Royalty Base:	Net Sales	
11		Licensors:	Leo Pharma A/S	Tiered Royalty:	Yes	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Licensee:	Galen (Chemicals) Ltd.			
12		Duration:	20 year(s)	Exclusive:	Exclusive	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Other Payments:	United States			
13		Reference:	8053	Effective Date:	07/21/2005	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		SEC Code:	2834	SEC Filed Date:	11/09/2005	
14		SEC Filing:	Depomed Inc	Royalty Rate:	25.00 %	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Agreement Type:	10-Q PDF	Royalty Base:	Net Sales	
15		Licensors:	Patent	Tiered Royalty:	Yes	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Licensee:	Depomed Inc			
16		Duration:	Esprit Pharma Inc	Exclusive:	Exclusive	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Other Payments:	20 year(s)			
17		Territory:	United States			Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Reference:	10711	Effective Date:	01/01/2007	
18		SEC Code:	2834	SEC Filed Date:	02/26/2007	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		SEC Filing:	Auriga Laboratories, Inc.	Royalty Rate:	50.00 %	
19		Licensors:	B-K PDF	Royalty Base:	Net Sales	Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Licensee:	Asset Purchase	Tiered Royalty:	Yes	
20		Agreement Type:	Trademark			Amendment to settlement regarding the "Levalli" brand of cough and cold medication, including Levall 12, Levall 5, Levall-G and other products.
		Reference:	10711	Effective Date:	01/01/2007	

	Licensors: Auriga Laboratories, Inc.
Licensees: Athlon Pharmaceuticals, Inc.	
Duration: Unknown	Exclusive: Unknown
Other Payments: Unknown	
Territory: Unknown	

 **Statistics**  **Go**  **New Folder**

[Move Docs To](#) | [Copy Docs To](#) | [Go To](#) **2834 - Patent (9)** 



[Subscribe](#) | [Royalty Rate Search](#) | [Library](#) | [Valuation](#)
[Intellectual Property](#) | [Intangible Assets](#) | [Royalty Rates](#)
[Contact Us](#) | [Home](#)

Copyright © RoyaltyStat LLC 04/17/2009
Website by Woodbourne Solutions